Abivax SA
PAR:ABVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Asdion Bhd
KLSE:ASDION
|
MY |
|
RaffAello-Astrum Financial Holdings Ltd
HKEX:8333
|
HK |
|
James Hardie Industries PLC
NYSE:JHX
|
IE |
|
L
|
Lakhotia Polyesters (India) Ltd
BSE:535387
|
IN |
|
Fuso Dentsu Co Ltd
TSE:7505
|
JP |
Abivax SA
Cash
Abivax SA
Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abivax SA
PAR:ABVX
|
Cash
€57m
|
CAGR 3-Years
28%
|
CAGR 5-Years
14%
|
CAGR 10-Years
85%
|
|
|
Valneva SE
PAR:VLA
|
Cash
€109.7m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Cash
$45.9m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-17%
|
|
|
DBV Technologies SA
PAR:DBV
|
Cash
$127.1m
|
CAGR 3-Years
62%
|
CAGR 5-Years
25%
|
CAGR 10-Years
-3%
|
|
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
See Also
What is Abivax SA's Cash?
Cash
57m
EUR
Based on the financial report for Dec 31, 2025, Abivax SA's Cash amounts to 57m EUR.
What is Abivax SA's Cash growth rate?
Cash CAGR 10Y
85%
Over the last year, the Cash growth was 0%. The average annual Cash growth rates for Abivax SA have been 28% over the past three years , 14% over the past five years , and 85% over the past ten years .
